Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$76,178.00-0.96%ETH$2,419.58-2.27%GOLD$4,388.30+1.28%OIL$103.42-2.28%
Smart Investors Daily
IO

NASDAQ · IOVA

Iovance Biotherapeutics, Inc.

Healthcare · Biotechnology

$9.36

Up+$0.10 (+1.08%)

Updated Sep 16, 2026, 11:09 AM

SID Score

6.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
744.64M
P/E ratio
-1.93
Dividend yield
0.00%
52-week range
$1.76 – $9.41
Volume
11.09M
Avg. volume
13.69M

Price performance

IOVA price history

1M range · 20 trading sessions · Daily adjusted prices

IOVA closed at $9.36 after 20 trading sessions, up 33.14% for the selected period.

Last close
$9.36
Period change
+33.14%
Period low
$7.03
Period high
$9.36
Daily close
View OHLC price history
IOVA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$9.21$9.38$8.98$9.3611.09M
Sep 14, 2026$8.56$9.41$8.54$9.2621.04M
Sep 11, 2026$8.25$8.695$8.075$8.6012.39M
Sep 10, 2026$8.32$8.4199$8.04$8.1410.57M
Sep 9, 2026$8.655$8.73$8.32$8.4311.94M
Sep 8, 2026$8.69$8.91$8.48$8.709.54M
Sep 4, 2026$8.74$8.90$8.635$8.798.08M
Sep 3, 2026$8.65$8.7897$8.55$8.7014.64M
Sep 2, 2026$8.31$8.69$8.295$8.6212.39M
Sep 1, 2026$8.02$8.29$7.97$8.286.76M
Aug 31, 2026$7.945$8.17$7.66$8.1712.13M
Aug 28, 2026$8.20$8.35$7.97$8.017.69M
Aug 27, 2026$8.08$8.3186$7.95$8.267.44M
Aug 26, 2026$8.34$8.55$8.02$8.0810.1M
Aug 25, 2026$8.16$8.48$8.0307$8.4411.91M
Aug 24, 2026$8.08$8.36$7.79$8.0615.73M
Aug 21, 2026$9.08$9.30$8.145$8.2927.81M
Aug 20, 2026$8.07$9.36$7.96$8.9943.81M
Aug 19, 2026$7.20$8.055$7.19$7.9924.25M
Aug 18, 2026$7.00$7.31$6.931$7.0310.5M

Latest IOVA news

The latest Smart Investors Daily articles mentioning IOVA.

Stock researchCompany · Overview

IOVA research

Overview

Company profile and research snapshot.

Company profile

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$14.25
Implied upside
—
Analysts
—
IOVA recent ratings
DateFirmRatingTarget
Aug 25, 2026TD CowenBuy—
Aug 20, 2026UBSNeutral—
Aug 18, 2026MizuhoOutperform—
Aug 7, 2026CitizensMarket Outperform—
Aug 7, 2026BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Iovance Biotherapeutics to Present at Upcoming Conferences

SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences: Wells Fargo 21st Annual Healthcare ConferenceFireside Chat: September 10, 2026, at 11:00 a.m. ETBoston, MA H.C. Wainwright 28th Annual Global

Yahoo · Aug 26, 2026

5 Biotech Stocks Worth Adding to Your Portfolio Now

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By